Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CyclopharmASX:CYC -3.70%39 3-1 Month Momentum % is -32.43% as of Jul. 28, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 39/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 122 Medical Distribution companies, Cyclopharm ranks worse than 86.07% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-28), Cyclopharm's 3-1 Month Momentum % is -32.43%.
The industry rank for Cyclopharm's 3-1 Month Momentum % or its related term are showing as below:
ASX:CYC's 3-1 Month Momentum % is ranked worse than 86.07% of 122
companies
in the Medical Distribution industry
Industry Median: -8.37
vs ASX:CYC: -32.43
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cyclopharm 3-1 Month Momentum % Related Terms
ASX:CYC vs MCK, COR, CAH: 3-1 Month Momentum % Comparison
For the Medical Distribution subindustry, Cyclopharm's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm 3-1 Month Momentum % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a 3-1 Month Momentum % of -32.43% as of Jul. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #105 out of 122 companies in the Medical Distribution industry, placing it in the top 86.1%.
Is Cyclopharm's 3-1 Month Momentum % too high?
Cyclopharm's current 3-1 Month Momentum % is -32.43%. Based on the distribution chart, Cyclopharm ranks #105 out of 122 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's 3-1 Month Momentum % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #105 out of 122 companies for 3-1 Month Momentum %. This places Cyclopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Distribution company?
A good 3-1 Month Momentum % depends on the Medical Distribution industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cyclopharm and its competitors. Cyclopharm's current 3-1 Month Momentum % is -32.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.52 — trading 37.3% below its estimated fair value. The current 3-1 Month Momentum % is -32.43%. Cyclopharm's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current 3-1 Month Momentum % is -32.43% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.52 is trading 37.3% below its estimated GF Value™ of A$0.83.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
3-1 Month Momentum %: -32.43%
GF Value™: A$0.83 vs. price of A$0.52 (37.3% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
39GF Score
Get the complete analysis for ASX:CYC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
